HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS Psychiatric Bulletin Advances in Psychiatric Treatment All RCPsych Journals		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Related articles in BJP Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by PARK, S. Articles by SOUMERAI, S. B. Search for Related Content PubMed PubMed Citation Articles by PARK, S. Articles by SOUMERAI, S. B.

Effect of switching antipsychotics on antiparkinsonian medication use in schizophrenia

Population-based study

Department of Ambulatory Care and Prevention, Harvard Medical School and Harvard Pilgrim Health Care, Boston, USA, and Korea Health Industry Development Institute, Seoul, Korea

DENNIS ROSS-DEGNAN, ScD, ALYCE S. ADAMS, PhD and JAMES SABIN, MD

Department of Ambulatory Care and Prevention, Harvard Medical School and Harvard Pilgrim Health Care, Boston, USA

PANOS KANAVOS, PhD

London School of Economics and Political Science, London, UK

STEPHEN B. SOUMERAI, ScD

Department of Ambulatory Care and Prevention, Harvard Medical School and Harvard Pilgrim Health Care, Boston, USA

Correspondence: Dr Sylvia Park, Korea Health Industry Development Institute, 57-1Noryangjin-Dong, Dongjak-GU, Seoul 156-800, Republic of Korea. E-mail: sylviap{at}khidi.or.kr

Declaration of interest None. Funding detailed in Acknowledgements.

Background The extent to which atypical antipsychotics have a lower incidence of extrapyramidal symptoms than typical antipsychotics has not been well-evaluated in community practice.

Aims To examine the effects of switching antipsychotics on antiparkinsonian medication use among individuals with schizophrenia in UK general practices.

Method We included those switched from typical to atypical antipsychotics (n=209) or from one typical antipsychotic to another (n=261) from 1994 to 1998.

Results Antiparkinsonian drug prescribing dropped by 9.2% after switching to atypical antipsychotics (P<0.0001). Switching to olanzapine decreased the rate by 19.2% (P<0.0001), but switching to risperidone had no impact. After switching from one typical antipsychotic to another, antiparkinsonian drug prescribing increased by 12.9% (P<0.0001).

Conclusions Reduction in antiparkinsonian medication use after switching to atypical antipsychotics was substantial in community practice but not as large as in randomised controlled trials. The rate of reduction varied according to the type of medication.

Related articles in BJP:

Highlights of this issue

KIMBERLIE DEAN
BJP 2005 187: 101-a5. [Full Text]  

PETER TYRER
BJP 2005 187: 202. [Full Text]  

This article has been cited by other articles:

				S. Grover and P. Kulhara Antiparkinsonian prescription and extrapyramidal symptoms The British Journal of Psychiatry, May 1, 2006; 188(5): 492 - 492. [Full Text] [PDF]

				P. J. Weiden Switching antipsychotics: an updated review with a focus on quetiapine J Psychopharmacol, January 1, 2006; 20(1): 104 - 118. [Abstract] [PDF]